z-logo
open-access-imgOpen Access
Engineering-enhanced CAR T cells for improved cancer therapy
Author(s) -
Michael C. Milone,
Jie Xu,
SaiJuan Chen,
McKensie Collins,
Jianfeng Zhou,
Daniel J. Powell,
J. Joseph Melenhorst
Publication year - 2021
Publication title -
nature cancer
Language(s) - English
Resource type - Journals
ISSN - 2662-1347
DOI - 10.1038/s43018-021-00241-5
Subject(s) - chimeric antigen receptor , cd19 , cell therapy , car t cell therapy , t cell , antigen , medicine , cell , cancer research , immunotherapy , cancer , immunology , biology , immune system , genetics
Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells, the most developed of the CAR T-cell therapies. We discuss the many challenges to CAR-T therapeutic success and innovations in CAR design and T-cell engineering aimed at extending this therapeutic platform beyond hematologic malignancies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here